Olga Rivera Ballesteros from the Center for Infectious Medicine (CIM) at the Department of Medicine, Huddinge (MedH) is ...

A main obstacle to an HIV cure is that viral DNA integrates into the chromosomes of memory T cells (blue), which evade ...

A new method is developed to track dormant HIV-infected cells. This breakthrough may lead to new treatments that eliminate ...

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

For the majority of people with the virus in the U.S., dying with HIV has turned into living a long life with HIV.

Named after Indiana teenager Ryan White – who contracted HIV in 1984 after receiving an untested blood transfusion while ...

King Holmes, MD, PhD, an infectious diseases physician and researcher who helped create modern STI research and was a central figure in the early AIDS ... of HIV after receiving stem cell ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Sub-Saharan Africa, home to 25 million of the world's 38 million people living with HIV, is expected to bear the brunt.

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.